DDInter381 DDInter629
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634]
Cinacalcet {u} (Compound) resembles {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may lead to a major life threatening interaction when taken with {v} Eliglustat
Cinacalcet {u} (Compound) resembles {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Cinacalcet {u} (Compound) resembles {v} (Compound) Propranolol
Propranolol {u} (Compound) resembles {v} (Compound) Atomoxetine
Atomoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Cinacalcet {u} (Compound) resembles {v} (Compound) Etofenamate
Etofenamate {u} (Compound) resembles {v} (Compound) Fluoxetine
Fluoxetine {u} may lead to a major life threatening interaction when taken with {v} Eliglustat
Cinacalcet {u} (Compound) resembles {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Cinacalcet {u} (Compound) resembles {v} (Compound) Duloxetine
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Cinacalcet {u} (Compound) resembles {v} (Compound) Triflupromazine
Triflupromazine {u} (Compound) resembles {v} (Compound) Perphenazine
Perphenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Cinacalcet (Compound) resembles Dexfenfluramine (Compound) and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may lead to a major life threatening interaction when taken with Eliglustat
Cinacalcet (Compound) resembles Dexfenfluramine (Compound) and Dexfenfluramine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Cinacalcet (Compound) resembles Propranolol (Compound) and Propranolol (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Cinacalcet (Compound) resembles Etofenamate (Compound) and Etofenamate (Compound) resembles Fluoxetine (Compound) and Fluoxetine may lead to a major life threatening interaction when taken with Eliglustat
Cinacalcet (Compound) resembles Dexfenfluramine (Compound) and Dexfenfluramine may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Cinacalcet (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Cinacalcet (Compound) resembles Triflupromazine (Compound) and Triflupromazine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat